1 | we are very happy | | | | | | | 5 | 0.97% |
2 | 2023 we are very | | | | | | | 5 | 0.97% |
3 | are very happy to | | | | | | | 4 | 0.78% |
4 | summit 2023 we are | | | | | | | 4 | 0.78% |
5 | very happy to attend | | | | | | | 3 | 0.58% |
6 | clinical and commercial supply | | | | | | | 3 | 0.58% |
7 | to attend to the | | | | | | | 3 | 0.58% |
8 | to the 14th world | | | | | | | 2 | 0.39% |
9 | of boston organized by hanson | | | | | | | 2 | 0.39% |
10 | annual world adc summit | | | | | | | 2 | 0.39% |
11 | world adc summit 2023 | | | | | | | 2 | 0.39% |
12 | happy to attend to | | | | | | | 2 | 0.39% |
13 | is proud to announce | | | | | | | 2 | 0.39% |
14 | proud to announce its | | | | | | | 2 | 0.39% |
15 | development clinical and commercial | | | | | | | 2 | 0.39% |
16 | attend to the 14th | | | | | | | 2 | 0.39% |
17 | boston organized by hanson wade | | | | | | | 2 | 0.39% |
18 | development summit 2023 we | | | | | | | 2 | 0.39% |
19 | and commercial supply for | | | | | | | 2 | 0.39% |
20 | by hanson wade the 14th | | | | | | | 2 | 0.39% |
21 | careers eprocurement sustainability privacy | | | | | | | 2 | 0.39% |
22 | as adcs conjugation and | | | | | | | 1 | 0.19% |
23 | and nano medicines bsp | | | | | | | 1 | 0.19% |
24 | oligonucleotides and nano medicines | | | | | | | 1 | 0.19% |
25 | proteins oligonucleotides and nano | | | | | | | 1 | 0.19% |
26 | peptides proteins oligonucleotides and | | | | | | | 1 | 0.19% |
27 | finish peptides proteins oligonucleotides | | | | | | | 1 | 0.19% |
28 | conjugation and fill finish | | | | | | | 1 | 0.19% |
29 | adcs conjugation and fill | | | | | | | 1 | 0.19% |
30 | molecules as adcs conjugation | | | | | | | 1 | 0.19% |
31 | technologically developed to meet | | | | | | | 1 | 0.19% |
32 | large molecules as adcs | | | | | | | 1 | 0.19% |
33 | and large molecules as | | | | | | | 1 | 0.19% |
34 | small and large molecules | | | | | | | 1 | 0.19% |
35 | handle small and large | | | | | | | 1 | 0.19% |
36 | to handle small and | | | | | | | 1 | 0.19% |
37 | therapeutics applications facilities designed | | | | | | | 1 | 0.19% |
38 | of a product from | | | | | | | 1 | 0.19% |
39 | a product from the | | | | | | | 1 | 0.19% |
40 | formulation and process developmentoptimization | | | | | | | 1 | 0.19% |